Full Papers
Secukinumab real world drug retention compared to TNF-alpha inhibitors in psoriatic arthritis
T. Eviatar1, D. Zisman2, O. Gendelman3, T. Reitblat4, A. Balbir-Gurman5, T. Mashiach6, R. Almog7, O. Elkayam8
- Department of Rheumatology, Tel Aviv Sourasky Medical Center, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. talieviatar@gmail.com
- Department of Rheumatology, Carmel Medical Center, Haifa, and The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel.
- Sackler Faculty of Medicine, Tel Aviv University, and Rheumatology Unit, The Zabludowicz Center for Autoimmune Diseases, Tel-Hashomer, Ramat Gan, Israel.
- Rheumatology Unit, Barzilai Medical Center, Ashkelon, Israel.
- The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, and B. Shine Rheumatology Institute, Rambam Health Care Campus, Haifa, Israel.
- Epidemiology and Biostatistics Unit, Rambam Health Care Campus, Haifa, Israel.
- Epidemiology and Biostatistics Unit, Rambam Health Care Campus, Haifa, Israel.
- Department of Rheumatology, Tel Aviv Sourasky Medical Center, and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
CER14090
2022 Vol.40, N°1
PI 0015, PF 0023
Full Papers
Free to view
(click on article PDF icon to read the article)
PMID: 33427613 [PubMed]
Received: 02/10/2020
Accepted : 01/12/2020
In Press: 07/01/2021
Published: 28/01/2022
Abstract
OBJECTIVES:
To prospectively study real-world efficacy and safety of secukinumab in psoriatic arthritis (PsA) patients from the Israeli registry of inflammatory diseases.
METHODS:
PsA patients fulfilling the CASPAR criteria were included in the analysis from 2010 to 2019. The primary endpoint was secukinumab drug retention compared to other TNF-α inhibitors (TNFi). Bivariate and multivariate analyses were made by Cox regression analysis. Drug retention according to treatment line was examined with Kaplan-Meier curves.
RESULTS:
Included were 404 PsA patients who had 709 treatment courses during the study period. Ninety patients had been treated with secukinumab (22%). The secukinumab-treated patients were significantly older and their disease duration was longer. Secukinumab was less likely to be the first line of treatment compared to TNFi. Secukinumab had a drug retention comparable to TNFi, and a better drug retention than TNFi among biologic-experienced patients. Neither methotrexate combination nor body mass index affected the inefficacy event rate. Secukinumab had a similar rate of adverse events as TNFi.
CONCLUSIONS:
This multicentre real-world study demonstrated that secukinumab had a drug retention comparable to TNFi. Secukinumab had a better drug retention than TNFi among biologic-experienced patients. IL-17 inhibition is an effective mechanism of action to treat PsA in real life.
